Maverick Therapeutics and Takeda collaboration includes acquisition option
USA-based Maverick Therapeutics, an MPM Capital portfolio company, has entered a collaboration to develop its T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer with Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502).
The $125 million of proposed funding includes an upfront option, equity and research and development funding payments, and provides Takeda with the exclusive right to purchase Maverick after five years for an undisclosed sum. Maverick was founded in 2016, as a spin-out of its former parent, Harpoon Therapeutics.
The news comes just a few days after Takeda announced its decision to acquire Ariad Pharmaceuticals for $5.2 billion. Takeda also signed a deal giving it access to South Korean firm LegoChem Biosciences' proprietary antibody-drug conjugate (ADC) technology ConjuAll for the evaluation of next-generation ADC candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze